more cognitive assessments administered by the research team. Some researchers record health information related to participants' conduct during research that is not relevant to study outcomes, such as when a researcher conducting an interview study notes in the research record that an interview has been rescheduled or canceled due to a participant's illness or accident. In all of these examples, the recorded information presumably falls within the DRS because it was used to make decisions about individuals, but inconsistent institutional policies and practices suggest that there is confusion about these determinations. Without guidance from HHS, there is the potential that institutions will be sanctioned for unintentional violations of HIPAA and that research participants will be denied access to all of the information to which they are entitled.

We therefore propose that HHS clarify the kinds of research data that are eligible for access on request. The guidance should describe use cases involving research data that are part of the DRS, research data that are not part of the DRS (and the justification for their exclusion), and what changes to those use cases would compel different conclusions.

Finally, we propose that the guidance be developed by a task force comprising regulators, researchers, and members of the public. In the past, HHS issued FAQs detailing covered entities' obligations with respect to the HIPAA access right without robust expert or public input⁶. We believe that such input would improve the value of the guidance to regulated entities and also that public participation in the process is warranted given that the

access right was adopted for the public's benefit. After publishing this guidance, the task force should regularly review and update it to account for emerging practices and technical capabilities that are certain to further expand the kinds of data that are generated and used in research. The public-minded spirit of the HIPAA access right seems to compel no less than a long-term commitment to resolving new questions about access as those data evolve.

Conclusions

Because of a clear trend toward more engagement and transparency with research participants, we should expect more research participants to exercise their HIPAA access right in coming years. The committee's recommendations ensure that researchers are able to return information meeting high quality standards without fear of violating CLIA. Our additional recommendations help researchers satisfy their HIPAA obligations more efficiently and consistently.

Christi J. Guerrini¹, Jeffrey R. Botkin² and Amy L. McGuire^{1*}

¹Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA. ²The University of Utah School of Medicine, Salt Lake City, UT, USA.

*e-mail: amcguire@bcm.edu

Published online: 23 July 2019 https://doi.org/10.1038/s41587-019-0190-3

References

- 1. 45 C.F.R. § 164.524.
- National Academies of Sciences, Engineering, and Medicine. Returning Individual Research Results to Participants: Guidance for a New Research Paradigm (National Academies Press, 2018).
- 3. 45 C.F.R. § 160.103.

- 4. 45 C.E.R. § 164.501.
- 5. Federal Register 65, 82461–82829 (2000).
- Department of Health and Human Services. Individuals' right under HIPAA to access their health information. 45 CFR § 164.524. https://www.hhs.gov/hipaa/for-professionals/privacy/ guidance/access/index.html#newlyreleasedfaqs (2016).
- 7. 45 C.F.R. §§ 160.312, 160.402, 160.404.
- 8. Federal Register 79, 7289-7316 (2014).
- Meyers, P. CLIA and research results. HHS.gov http://wayback. archive-it.org/org-745/20150824191143/http://www.hhs.gov/ ohrp/sachrp/mtgings/mtg03-11/rirr_by_p_meyers.pdf (2011).
- Centers for Medicare and Medicaid Services. Research testing and Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations. https://www.cms.gov/Regulations-and-Guidance/ Legislation/CLIA/Downloads/Research-Testing-and-CLIA.pdf (2014).
- 11. Wolf, S. M. & Evans, B. J. Return of results and data to research participants. *Science* **362**, 159–160 (2018).
- Barnes, M. et al. The CLIA-HIPAA conundrum of returning test results to research participants. Medical Research Law & Policy Report https://www.ropesgray.com/~/media/ Files/articles/2015/July/2015-07-15-Bloomberg-BNA.ashx (2015).
- Evans, B. J., Dorschner, M. O., Burke, W. & Jarvik, G. P. Regulatory changes raise troubling questions for genomic testing. *Genet. Med.* 16, 799–803 (2014).
- 14. Secretary's Advisory Committee on Human Research Protections. Attachment C: return of individual results and special considerations of issues arising from amendments of HIPAA and CLIA. https://www.hhs.gov/ohrp/sachrp-committee/ recommendations/2015-september-28-attachment-c/index.html (2015).
- Evans, B. J. & Wolf, S. M. A Faustian bargain that undermines research participants' privacy rights and return of results. Florida Law Rev. https://ssrn.com/abstract=3368555 (2019).

Acknowledgements

The views expressed in this article are those of the authors and, except where noted, do not represent the official position of the US National Academies of Sciences, Engineering, and Medicine or of the committee that produced the report discussed in this article.

Author contributions

C.J.G., J.R.B., and A.L.M. contributed to the conception and drafting of the manuscript. C.J.G. and A.L.M. conducted legal analysis.

Competing interests

J.R.B. chaired, and A.L.M. was a member of, the committee that produced the report discussed in this article. C.J.G. was a consultant to the committee.

Corrected: Author Correction

Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2

To the Editor — Rapid advances in DNA-sequencing and bioinformatics technologies in the past two decades have substantially improved understanding of the microbial world. This growing understanding relates to the vast diversity of microorganisms; how microbiota and microbiomes affect disease¹ and medical treatment²; how microorganisms affect the health of the planet³; and the nascent exploration of the medical⁴, forensic⁵, environmental⁶ and agricultural⁷

applications of microbiome biotechnology. Much of this work has been driven by marker-gene surveys (for example, bacterial/archaeal 16S rRNA genes, fungal internal-transcribed-spacer regions and eukaryotic 18S rRNA genes), which profile microbiota with varying degrees of taxonomic specificity and phylogenetic information. The field is now transitioning to integrate other data types, such as metabolite⁸, metaproteome⁹ or metatranscriptome^{9,10} profiles.

The QIIME 1 microbiome bioinformatics platform has supported many microbiome studies and gained a broad user and developer community. Interactions with QIIME 1 users in our online support forum, our workshops and direct collaborations have shown the platform's potential to serve an increasingly diverse array of microbiome researchers in academia, government and industry. Here, we present QIIME 2, a completely reengineered and rewritten system that is expected to




Fig. 1 | QIIME 2 provides many interactive visualization tools. The products of four worked examples are presented here, and interactive versions of these screen captures are available in Supplementary File 1 and at https://github.com/qiime2/paper1. Detailed descriptions and methods, including the commands used to generate each of these visualizations, are provided in Supplementary Methods. a, Unweighted UniFrac principal coordinate analysis plot containing 37,680 samples, illustrating the scalability of QIIME 2. Colors indicate sample type, as described by the Earth Microbiome Project ontology (EMPO). b, Interactive taxonomic composition bar plot illustrating the phylum-level composition of microbial-mat samples collected along a temperature gradient in Yellowstone National Park Hot Spring outflow channels (Steep Cone Geyser). The many interactive controls available in this plot vastly decrease the burden of exploratory analysis over QIIME 1. c, Feature volatility plot (https://msystems.asm.org/content/3/6/e00219-18) illustrating the change in *Bifidobacterium* abundance over time in breast-fed and formula-fed infants. Temporally interesting features can be interactively discovered with this visualization. Bar charts rank the importance (predictive power for time point) and mean abundance of all microbial features. These bar charts provide an interface for visualizing volatility plots (line plots) of individual features in the context of their importance and abundance; clicking on a bar will display the volatility plot of that feature and highlight in blue that feature's importance and abundance in the bar charts below. d, Molecular cartography of the human skin surface. Colored spots represent the abundance of the small-molecule cosmetic ingredient sodium laureth sulfate on the human skin. Sample data can be interactively visualized in three-dimensional models, thus supporting the discovery of spatial patterns.




Fig. 2 | QIIME 2 iteratively records data provenance, ensuring bioinformatics reproducibility. This simplified diagram illustrates the automatically tracked information regarding the creation of the taxonomy bar plot presented in Fig. 1c. QIIME 2 results (circles) contain network diagrams illustrating the data provenance stored in the result. Actions (quadrilaterals) are applied to QIIME 2 results and generate new results. Arrows indicate the flow of QIIME 2 results through actions. TaxonomicClassifier and FeatureData[Sequence] inputs contain independent provenance (red and blue, respectively) and are provided to a classify action (yellow), which taxonomically annotates sequences. The result of the classify action, a FeatureData[Taxonomy] result, integrates the provenance of both inputs with the classify action. This result is then provided to the barplot action with a FeatureTable[Frequency] input, which shares some provenance with the FeatureData[Sequence] input, because they were generated from the same upstream analysis. The resulting visualization (Fig. 1c) has the complete data provenance and correctly identifies shared processing of inputs. This simplified representation was created manually from the complete provenance graph for the purpose of illustration. An interactive and complete version of this provenance graph (as well as those for other Fig. 1 panels) can be accessed through Supplementary File 1.

facilitate reproducible and modular analysis of microbiome data to enable the next generation of microbiome science.

QIIME 2 was developed on the basis of a plugin architecture (Supplementary Fig. 1) that allows third parties to contribute functionality (https://library.qiime2.org). QIIME 2 plugins exist for latest-generation tools for sequence

quality control from different sequencing platforms (DADA2 (ref. 11) and Deblur 12), taxonomy assignment¹³ and phylogenetic insertion¹⁴, which quantitatively improve the results over QIIME 1 and other tools (as detailed in the corresponding tool-specific publications). The plugins also support qualitatively new functionality, including microbiome paired-sample and time-series analysis¹⁵ (which are critical for studying the effects of treatments on the microbiome), and machine learning16. Trained machine learning models can be saved for application to new data and interrogated to identify important microbiome features. Several recently released plugins, including q2-cscs¹⁷, q2-metabolomics¹⁸, q2-shogun¹⁹, q2-metaphlan2 (ref. 20) and q2-picrust2 (ref. 21), provide initial support for analysis of metabolomics and shotgun metagenomics data. We are currently working with teams developing bioinformatics tools for metatranscriptomics and metaproteomics, and we expect to add new plugins supporting these data types to the ecosystem shortly. Additionally, many of the existing 'downstream' analysis tools, such as q2-sample-classifier¹⁶, can already work with these data types individually or in combination if they are provided in a feature table. Thus, QIIME 2 has the potential to serve not only as a marker-gene analysis tool but also a multidimensional and powerful data science platform that can be rapidly adapted to analyze diverse microbiome features.

QIIME 2 provides many new interactive visualization tools facilitating exploratory analyses and result reporting. Static versions of interactive visualizations resulting from four worked examples are provided in Fig. 1. QIIME 2 View (https://view.qiime2.org) is a unique new service (Supplementary Methods) that allows users to securely share and interact with results without installing QIIME 2. The QIIME 2 visualizations presented in Fig. 1 are provided in Supplementary File 1 to allow readers to interact with QIIME 2 View. Corresponding worked QIIME 2 example code is provided in the Supplementary Methods.

Reproducibility, transparency and clarity of microbiome data science are guiding principles in QIIME 2 design. To this end, QIIME 2 includes a decentralized data-provenance tracking system: details of all analysis steps with references to intermediate data are automatically stored in the results. Users can thus retrospectively determine exactly how any result was generated (Fig. 2 illustrates a simplified provenance graph derived from the data provenance of Fig. 1c). QIIME 2 also detects corrupted results indicating that

the provenance is no longer reliable and the results no longer contain information enabling reproducibility. The provenance of the visualizations presented in Fig. 1 can be interactively reviewed by loading the contents of Supplementary File 1 with QIIME 2 View, providing far more detailed information than can typically be provided in Methods text. QIIME 2 results are also semantically typed (Fig. 2), and actions indicate acceptable input types, clarifying the data that actions should be applied to and making complex workflows less error prone. Complex workflows can be created and shared by using Jupyter Notebooks²² or Common Workflow Language (CWL)23, and support for other workflow engines is currently in development.

Finally, QIIME 2 provides a softwaredevelopment kit (https://dev.qiime2. org) that can be used to integrate it as a component of other systems (such as Qiita24 or Illumina BaseSpace) and to develop interfaces targeted toward users with different levels of computational sophistication (Supplementary Fig. 2). QIIME 2 provides the QIIME 2 Studio graphical user interface and QIIME 2 View, interfaces designed for end-user biologists, clinicians and policy-makers; the QIIME 2 application programming interface, designed for data scientists who want to automate workflows or work interactively in Jupyter Notebooks²²; and q2cli and q2cwl, providing a command-line interface and CWL²³ wrappers for QIIME 2, designed for experts in high-performance computing. At present, computationally expensive steps support parallel computing at the individual-action level (for example, many actions including de-noising and taxonomy assignment support multiple threads). We are currently developing deeper integration with parallelism strategies available in third-party workflow engines, and workflow-level parallelism is currently possible through CWL.

There are many other powerful opensource software tools for microbiome data science, including mothur²⁵, phyloseq²⁶ and related tools available through Bioconductor²⁷, and the biobakery suite^{20,21,28}. The microbiome bioinformatics platform mothur is often compared to QIIME 1 and QIIME 2. A major difference between mothur and OIIME lies in the interactive visualizations: OIIME 2 provides many interactive visualization tools (several examples are provided in Fig. 1), whereas mothur focuses on generating data that can be easily loaded and visualized with other tools. The phyloseq tool focuses on microbiome statistical analysis and generating publication-ready visualizations

854

but, unlike OIIME 2, begins with a feature or operational-taxonomic-unit table. leaving 'upstream' processing steps, such as sequence demultiplexing and quality control, to other processing pipelines, many of which (like phyloseq) are available through Bioconductor. The biobakery suite provides analytic functionality that complements that of QIIME 2, and we are actively working with biobakery developers to support interoperability by making their tools accessible as QIIME 2 plugins (for example, the q2-metaphlan2 plugin allows users to run MetaPhlAn2 through QIIME 2). QIIME 2 provides the only Python-based microbiome data-science platform that supports retrospective data-provenance tracking to ensure reproducibility, multi-omics analysis support, interfaces geared toward different user types to enhance usability and an extensibility-focused design through the plugin architecture and softwaredevelopment kit. We share feedback from users of QIIME 2 on these and other features in Supplementary Methods.

The tools described in the preceding paragraph are all interoperable through plugins, exchange of files in standard formats or using multi-language environments, such as Jupyter Notebooks²². For example, the BIOM format²⁹ is supported by all of them. A diverse ecosystem of interoperable software is beneficial for the field, because it allows both experienced users to obtain multiple perspectives on their data and novice bioinformaticians to work in the programming environments that they are most comfortable with (for example, phyloseq allows users to work in R, whereas QIIME 2 allows users to work in Python). We plan to continue working with the developers of these tools, and with organizations such as the Genomics Standards Consortium, on plugins and standards to ensure interoperability, as well as developing tools to automatically import data from microbiome data-sharing platforms such as Qiita, the European Bioinformatics Institute (EBI) European Read Archive and the National Center for Biotechnology Information (NCBI) Sequence Read Archive.

Advances in microbiome research promise to improve many aspects of health and the world, and QIIME 2 will help drive those advances by enabling accessible, community-driven microbiome data science.

Data availability

Data for the analyses presented in Fig. 1 are available as follows: Earth Microbiome

Project data in Fig. 1a were obtained from ftp://ftp.microbio.me/emp/release1, and the American Gut Project (AGP) data were obtained from Qiita (http://qiita.microbio.me) study ID 10317. Sequence data in Fig. 1b are available in Qiita under study ID 10249 and the EBI under accession number ERP016173. Sequence data in Fig. 1c are available in Qiita under study ID 925 and the EBI under accession number ERP022167. Data in Fig. 1d are available in the q2-ili GitHub repository (https://github.com/biocore/q2-ili). Interactive versions of the Fig. 1 visualizations can be accessed at https://github.com/qiime2/paper1.

Code availability

QIIME 2 is open source and free for all use, including commercial. It is licensed under a BSD three-clause license. Source code is available at https://github.com/qiime2. Help for QIIME 2 is provided at https://forum.qiime2.org.

 $Editor's\ Note:\ This\ paper\ has\ been\ peer-reviewed.$

Evan Bolyen 1,80, Jai Ram Rideout 1,80, Matthew R. Dillon 1,80, Nicholas A. Bokulich (1)80, Christian C. Abnet (1)2, Gabriel A. Al-Ghalith 3, Harriet Alexander 4,5, Eric J. Alm 6,7, Manimozhiyan Arumugam 8, Francesco Asnicar 9, Yang Bai 10,11,12, Jordan E. Bisanz 13, Kyle Bittinger 14,15, Asker Brejnrod⁸, Colin J. Brislawn¹⁶, C. Titus Brown 5, Benjamin J. Callahan 17,18, Andrés Mauricio Caraballo-Rodríguez 19, John Chase¹, Emily K. Cope^{1,20}, Ricardo Da Silva¹⁹, Christian Diener 21, Pieter C. Dorrestein 19, Gavin M. Douglas²², Daniel M. Durall ²³ Claire Duvallet 6, Christian F. Edwardson 24, Madeleine Ernst^{19,25}, Mehrbod Estaki²⁶, Jennifer Fouquier 27,28, Julia M. Gauglitz 19, Sean M. Gibbons 21,29, Deanna L. Gibson 30,31, Antonio Gonzalez³², Kestrel Gorlick¹, Jiarong Guo³³, Benjamin Hillmann³⁴, Susan Holmes 135, Hannes Holste 32,36, Curtis Huttenhower (D37,38, Gavin A. Huttley39, Stefan Janssen 1040, Alan K. Jarmusch 19, Lingjing Jiang⁴¹, Benjamin D. Kaehler^{39,42}, Kyo Bin Kang (D) 19,43, Christopher R. Keefe (D), Paul Keim¹, Scott T. Kelley⁴⁴, Dan Knights^{34,45}, Irina Koester^{19,46}, Tomasz Kosciolek ^{19,46}, Jorden Kreps 1, Morgan G. I. Langille 48, Joslynn Lee⁴⁹, Ruth Ley^{50,51}, Yong-Xin Liu^{10,11}, Erikka Loftfield 2, Catherine Lozupone 28, Massoud Maher⁵², Clarisse Marotz[©]³² Bryan D. Martin 53, Daniel McDonald 32, Lauren J. McIver^{37,38}, Alexey V. Melnik¹⁹, Jessica L. Metcalf⁵⁴, Sydney C. Morgan⁵⁵, Jamie T. Morton^{32,52}, Ahmad Turan Naimey¹, Jose A. Navas-Molina (1)32,52,56, LouisFelixNothias¹⁹,StephanieB.Orchanian¹⁹⁵⁷, Talima Pearson 1, Samuel L. Peoples 58,59, Daniel Petras 19, Mary Lai Preuss60,

Elmar Pruesse²⁸, Lasse Buur Rasmussen⁸ Adam Rivers 61, Michael S. Robeson II 62, Patrick Rosenthal⁶⁰, Nicola Segata⁹, Michael Shaffer^{27,28}, Arron Shiffer¹, RashmiSinha², SeJinSong D³², John R. Spear 63, Austin D. Swafford⁵⁷, Luke R. Thompson 64,65, Pedro J. Torres⁶⁶, Pauline Trinh⁶⁷, Anupriya Tripathi 19,32,68, Peter J. Turnbaugh 69, Sabah Ul-Hasan 70, Justin J. J. vander Hooft 171, Fernando Vargas⁶⁸, Yoshiki Vázquez-Baeza³², Emily Vogtmann[©]², Max von Hippel[©]⁷², William Walters⁵⁰, Yunhu Wan², Mingxun Wang¹⁹, Jonathan Warren ¹⁹, Kyle C. Weber^{61,74}, Charles H. D. Williamson⁷⁵, Amy D. Willis 76 , Zhenjiang Zech Xu³², Jesse R. Zaneveld⁷⁷, Yilong Zhang⁷⁸, Qiyun Zhu 132, Rob Knight 132,57,79 and J. Gregory Caporaso 1,20*

¹Center for Applied Microbiome Science, Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA. 2Metabolic Epidemiology Branch, National Cancer Institute, Rockville, MD, USA. 3Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, USA. 4Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA, USA. 5Department of Population Health and Reproduction, University of California, Davis, Davis, CA, USA. ⁶Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. 7Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA. 8Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 9Centre for Integrative Biology, University of Trento, Trento, Italy. ¹⁰State Key Laboratory of Plant Genomics, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China. 11 Centre of Excellence for Plant and Microbial Sciences (CEPAMS), Institute of Genetics and Developmental Biology, Chinese Academy of Sciences & John Innes Centre, Beijing, China. 12 University of Chinese Academy of Sciences, Beijing, China. 13 Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA. ¹⁴Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 15 Hepatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 16 Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA. ¹⁷Department of Population Health & Pathobiology, North Carolina State University, Raleigh, NC, USA. ¹⁸Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA. 19 Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA. ²⁰Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, USA. 21 Institute for Systems Biology, Seattle, WA, USA. ²²Department of Microbiology and Immunology, Dalhousie University,

Halifax, Nova Scotia, Canada. 23 Irving K. Barber School of Arts and Sciences, University of British Columbia, Kelowna, British Columbia, Canada, 24A. Watson Armour III Center for Animal Health and Welfare, Aquarium Microbiome Project, John G. Shedd Aquarium, Chicago, IL, USA. 25 Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. ²⁶Department of Biology, University of British Columbia Okanagan, Okanagan, British Columbia, Canada. ²⁷Computational Bioscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ²⁸Department of Medicine, Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 29eScience Institute, University of Washington, Seattle, WA, USA. 30 Irving K. Barber School of Arts and Sciences, Department of Biology, University of British Columbia, Kelowna, British Columbia, Canada. 31 Department of Medicine, University of British Columbia, Kelowna, British Columbia, Canada. 32 Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. 33 Center for Microbial Ecology, Michigan State University, East Lansing, MI, USA. 34Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, USA. 35 Statistics Department, Stanford University, Palo Alto, CA, USA. ³⁶Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA. ³⁷Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 38 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 39 Research School of Biology, The Australian National University, Canberra, Australian Capital Territory, Australia. 40 Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany. 41 Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 42School of Science, University of New South Wales, Canberra, Australian Capital Territory, Australia. 43 College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea. 44Department of Biology, San Diego State University, San Diego, CA, USA. 45 Biotechnology Institute, University of Minnesota, Saint Paul, MN, USA. 46 Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA. 47 Department of Pediatrics, University of California San Diego, La Jolla, California, USA. ⁴⁸Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada. 49Science Education, Howard Hughes Medical Institute, Ashburn, VA, USA. 50 Department of Microbiome Science, Max Planck Institute for Developmental Biology, Tübingen, Germany. 51 Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA. 52Department of Computer Science & Engineering, University of California San Diego, La Jolla, CA, USA. 53 Department of Statistics, University of Washington, Seattle, WA, USA. 54 Department of Animal Science, Colorado State University, Fort Collins, CO, USA. 55 Irving K. Barber School of Arts

and Sciences, Unit 2 (Biology), University of British Columbia, Kelowna, British Columbia, Canada. ⁵⁶Google LLC, Mountain View, CA, USA, ⁵⁷Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA. 58 School of Information Studies, Syracuse University, Syracuse, NY, USA. ⁵⁹School of STEM, University of Washington Bothell, Bothell, WA, USA. 60 Department of Biological Sciences, Webster University, St. Louis, MO, USA. 61 Agricultural Research Service, Genomics and Bioinformatics Research Unit, United States Department of Agriculture, Gainesville, FL, USA. 62College of Medicine, Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 63 Department of Civil and Environmental Engineering, Colorado School of Mines, Golden, CO, USA. 64Department of Biological Sciences and Northern Gulf Institute, University of Southern Mississippi, Hattiesburg, MS, USA. 65Ocean Chemistry and Ecosystems Division, Atlantic Oceanographic and Meteorological Laboratory, National Oceanic and Atmospheric Administration, La Jolla, CA, USA. 66 Department of Biology, San Diego State University, San Diego, CA, USA. ⁶⁷Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA. 68Division of Biological Sciences, University of California San Diego, San Diego, CA, USA. 69Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA. 70 Quantitative and Systems Biology Graduate Program, University of California Merced, Merced, CA, USA. 71Bioinformatics Group, Wageningen University, Wageningen, the Netherlands. 72Department of Mathematics, University of Arizona, Tucson, AZ, USA. 73National Laboratory Service, Environment Agency, Starcross, UK. 74College of Agriculture and Life Sciences, University of Florida, Gainesville, FL, USA. ⁷⁵Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA. 76Department of Biostatistics, University of Washington, Seattle, WA, USA. ⁷⁷School of STEM, Division of Biological Sciences, University of Washington Bothell, Bothell, WA, USA. 78Merck & Co. Inc., Kenilworth, NJ, USA. ⁷⁹Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA. 80 These authors contributed equally: Evan Bolyen, Jai Ram Rideout, Matthew R. Dillon, Nicholas A. Bokulich.

*e-mail: greg.caporaso@nau.edu

Published online: 24 July 2019 https://doi.org/10.1038/s41587-019-0209-9

References

- 1. Smith, M. I. et al. Science 339, 548–554 (2013).
- 2. Gopalakrishnan, V. et al. Science 359, 97-103 (2018).
- Gehring, C. A., Sthultz, C. M., Flores-Rentería, L., Whipple, A. V. & Whitham, T. G. Proc. Natl Acad. Sci. USA 114, 11169–11174 (2017).
- Lee, K., Pletcher, S. D., Lynch, S. V., Goldberg, A. N. & Cope, E. K. Front. Cell. Infect. Microbiol. 8, 168 (2018).
- 5. Metcalf, J. L. et al. *Science* **351**, 158–162 (2016).
- 6. Rubin, R. L. et al. Ecol. Appl. 28, 1594–1605 (2018).
- 7. Pineda, A., Kaplan, I. & Bezemer, T. M. Trends Plant Sci. 22,

770-778 (2017).

- 8. Kapono, C. A. et al. Sci. Rep. 8, 3669 (2018).
- 9. Verberkmoes, N. C. et al. ISME J. 3, 179-189 (2009).
- 10. Barr, T. et al. Gut Microbes 9, 338-356 (2018).
- 11. Callahan, B. J. et al. *Nat. Methods* **13**, 581–3 (2016). 12. Amir, A. et al. *mSystems* **2**, e00191–16 (2017).
- 13. Bokulich, N. A. et al. Microbiome 6, 90 (2018).
- 14. Janssen, S. et al. *mSystems* **3**, e00021–18 (2018).
- 15. Bokulich, N. A. et al. mSystems 3, e00219–18 (2018).
- 16. Bokulich, N. et al. J. Open Source Softw. 3, 934 (2018).
- Sedio, B. E., Rojas Echeverri, J. C., Boya, P. C. A. & Wright, S. J. Ecology 98, 616–623 (2017).
- 18. Wang, M. et al. Nat. Biotechnol. 34, 828-837 (2016).
- 19. Hillmann, B. et al. mSystems 3, e00069-18 (2018).
- 20. Truong, D. T. et al. Nat. Methods 12, 902-903 (2015).
- 21. Langille, M. G. I. et al. Nat. Biotechnol. 31, 814–821 (2013).
- Kluyver, T. et al. Positioning and power in academic publishing: players, agents and agendas. in Proc. 20th International Conference on Electronic Publishing (eds Loizides, F. & Schmidt, B.) 87–90
- 23. Amstutz, P. et al. https://doi.org/10.6084/m9.figshare.3115156.v2 (2016).
- 24. Gonzalez, A. et al. Nat. Methods 15, 796-798 (2018).
- 25. Schloss, P. D. et al. Appl. Environ. Microbiol. 75, 7537-7541 (2009).
- 26. McMurdie, P. J. & Holmes, S. PLoS One 8, e61217 (2013).
- 27. Huber, W. et al. Nat. Methods 12, 115-121 (2015).
- 28. Franzosa, E. A. et al. Nat. Methods 15, 962-968 (2018).
- 29. McDonald, D. et al. Gigascience 1, 7 (2012).

Acknowledgements

(IOS Press, 2016).

QIIME 2 development was primarily funded by NSF Awards 1565100 to I.G.C. and 1565057 to R.K. Partial support was also provided by the following: grants NIH U54CA143925 (J.G.C. and T.P.) and U54MD012388 (J.G.C. and T.P.); grants from the Alfred P. Sloan Foundation (J.G.C. and R.K.); ERCSTG project MetaPG (N.S.); the Strategic Priority Research Program of the Chinese Academy of Sciences QYZDB-SSW-SMC021 (Y.B.); the Australian National Health and Medical Research Council APP1085372 (G.A.H., J.G.C., Von Bing Yap and R.K.); the Natural Sciences and Engineering Research Council (NSERC) to D.L.G.; and the State of Arizona Technology and Research Initiative Fund (TRIF), administered by the Arizona Board of Regents, through Northern Arizona University. All NCI coauthors were supported by the Intramural Research Program of the National Cancer Institute. S.M.G. and C. Diener were supported by the Washington Research Foundation Distinguished Investigator Award. Thanks to the Yellowstone Center for Resources for research permit no. 5664 to I.R.S. for Yellowstone access and sample collection. We thank P. J. McMurdie for helpful discussion on the relationships between QIIME 2 and phyloseq. We would like to thank the users of QIIME 1 and 2, whose invaluable feedback has shaped QIIME 2. In particular, we would like to thank A. Abdelfattah (Stockholm University, Sweden), R. C. T. Boutin (University of British Columbia, Canada), D. J. Bradshaw II (Florida Atlantic University Harbor Branch Oceanographic Institute, USA), L. Bullington (MPG Ranch, USA), J. W. Debelius (Karolinska Institutet, Sweden), C. Duvallet (Massachusetts Institute of Technology, USA), E. Korzune Ganda (Cornell University, USA), A. Mahnert (Medical University of Graz, Austria), M. C. Melendrez (St. Cloud State University, USA), D. O'Rourke (University of New Hampshire, USA), A. R. Rivers (USDA ARS, USA), B. Sen (Tianjin University, China), S. Tangedal (Haukeland University Hospital and University of Bergen, Norway), P. J. Torres (San Diego State University, USA) and J. Warren (National Laboratory Service, UK) for writing end-user reviews included in the Supplementary Methods.

Author contributions

E.B., J.R.R., M.R.D., N.A.B., Y.B., J.E.B., C.J.B., A.M.C.-R., E.K.C., C. Diener, R.D., C.F.E., M. Ernst, M. Estaki, A.G., J.M.G., D.L.G., S.M.G., A.K.J., K.B.K., S.T.K., I.K., T.K., J.L., Y.-X.L., A.V.M., J.L.M., L.F.N., S.B.O., D.P., A.S., S.J.S., A.D.S., L.R.T., P. J. Torres, P. J. Turnbaugh, S.U.-H., F.V., J.W., R.K. and J.G.C. developed

documentation, educational materials and/or user/developer support content. E.B., J.R.R., M.R.D., N.A.B., R.K. and J.G.C. wrote the manuscript; all authors assisted with revision of the manuscript. E.B., J.R.R., M.R.D., N.A.B. and J.G.C. designed and developed the QIIME 2 framework. D.M.D., A.G., R.L., E.L., S.C.M., R.S., J.R.S., W.W., C.H.D.W. and R.K. contributed data used in the manuscript and/or testing of QIIME 2. C.C.A., C.T.B.,

E.K.C., P.C.D., S.H., P.K., E.L., T.P., R.S., E.V., Y.W. and R.K. contributed to the design of analytical methods. E.B., J.R.R., M.R.D., N.A.B., G.A.A.-G., H.A., E.J.A., M.A., F.A., K.B., A.B., B.J.C., J.C., G.M.D., C. Duvallet, M. Ernst, J.F., A.G., K.G., J.G., S.M.G., B.H., H.H., C.H., G.H., S.J., L.J., B.D.K., C.R.K., D.K., J.K., M.G.I.L., C.L., M.M., C.M., B.D.M., D.M., L.J.M., J.T.M., A.T.N., J.A.N.-M., S.L.P., M.L.P., E.P., L.B.R., A.R., M.S.R., P.R., N.S., M.S., P.T.,

A.T., J.J.J.v.d.H., Y.V.-B., M.V., M.W., K.C.W., A.D.W., Z.Z.X., J.R.Z., Y.Z., Q.Z. and J.G.C. contributed software to QIIME 2 plugins, interfaces, framework and/or build and test systems.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41587-019-0209-9.